Evidence map›Paper›PMID 36823658›Full record

ArticleJournal of medical case reports2023

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report.

Rajapillai L I Pillai, Caroline Dziel, Stephanie Vogel, Frank Szczerba, Weijen W Chang, Ingrid Y Camelo, Armando Paez

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rajapillai L I PillaiDepartment of Neurology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA. rajapillai.pillai@childrens.harvard.edu.ORCID http://orcid.org/0000-0003-4901-6663
Caroline DzielDepartment of Pediatrics, UMass-Chan Baystate, 759 Chestnut St, Springfield, MA, 01199, USA.
Stephanie VogelDepartment of Pediatrics, UMass-Chan Baystate, 759 Chestnut St, Springfield, MA, 01199, USA.
Frank SzczerbaDepartment of Pediatrics, UMass-Chan Baystate, 759 Chestnut St, Springfield, MA, 01199, USA.
Weijen W ChangDepartment of Pediatrics, UMass-Chan Baystate, 759 Chestnut St, Springfield, MA, 01199, USA.
Ingrid Y CameloDepartment of Pediatrics, Medical College of Georgia, 1120 15th St, Augusta, GA, 30912, USA.
Armando PaezDepartment of Medicine, UMass-Chan Baystate, 759 Chestnut St, Springfield, MA, 01199, USA.
University of Massachusetts Chan Medical School · USAugusta University · USBoston Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBamlanivimab and etesevimab had been granted emergency use authorization in children under 12 years who are at risk of progression from mild/moderate coronavirus disease 2019 to severe disease and hospitalization. CASE REPORT: We report on a 5-year-old white male with preexisting conditions, predisposing him to severe disease, who developed hypoxia and flushing 3 minutes into his infusion, thus meeting the criteria for anaphylaxis.

conclusionsWe believe this patient developed either an immunoglobulin E-mediated anaphylactic or a non-immunoglobulin E-mediated anaphylactoid reaction to bamlanivimab and etesevimab, which is an important possibility to consider on administration.

Indexed as

AnaphylaxisCOVID-19Antibodies, MonoclonalAntibodies, NeutralizingChildChild, PreschoolDrug CombinationsHospitalizationHumansMaleAntibodies, MonoclonalAntibodies, Neutralizingbamlanivimab and etesevimab drug combinationDrug CombinationsAnaphylactoidBamlanivimabCase reportEtesevimabInfusion reactionMonoclonal antibody

Identifiers

PMID36823658
PMCPMC9950013
OpenAlexW4321605155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.